Search - tctmd.com

Displaying 1 - 20 of 167

Sort: Relevancy | Date

Presentation CTO 2026

De Novo Disease: The Data and Ongoing Trails

Presenter: David E. Kandzari

February 13, 2026

Presentation TCT 2025

Where Do We See Renal Denervation in the Hypertension Pathway, Now and in Five Years?

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Under Pressure

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

NCD

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Welcome

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Safety and Feasibility of the Supira System in High-Risk Percutaneous Coronary Interventions: 90-Day Results from the US SUPPORT I Early Feasibility Study (EFS)

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Case 3: My Patient is on 6 Anti-Hypertensives - Are They Taking Them? and Is Renal Denervation Futile?

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Durable Safety and Efficacy of Renal Denervation using the Symplicity Spyral Catheter in Patients Taking Antihypertensive Drugs: Final, 3-Year Results from the SPYRAL HTN-ON MED Randomized Study

Presenter: David E. Kandzari

October 26, 2025

Presentation CTO 2025

Clinical Experience With a Novel Perfusion Balloon Catheter in Patients With Coronary Artery Perforation: Primary Results From the Ringer Clinical Study

Presenter: David Kandzari

March 01, 2025

Presentation THT 2025

What Are the Major Challenges?

Presenter: David Kandzari

February 13, 2025

Presentation TCT 2024

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

Presenter: David Kandzari

October 28, 2024

Presentation TCT 2024

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

Presenter: David Kandzari

October 28, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation THT 2024

Initial Results from the First-in-Human Study of the Supira System

Presenter: David E. Kandzari

March 06, 2024

Presentation TCT 2023

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

Presenter: David Kandzari

October 25, 2023

Presentation TCT 2023

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

Presenter: David Kandzari

October 25, 2023

Presentation TCT 2023

Securing Reimbursement: The Pathway to Financial Stability

Presenter: David Kandzari

October 24, 2023

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation TCT 2022

It’s Time We Had These Devices Approved and Reimbursed

Presenter: David E. Kandzari

September 18, 2022

Advertisement

De Novo Disease: The Data and Ongoing Trails

Where Do We See Renal Denervation in the Hypertension Pathway, Now and in Five Years?

Under Pressure

NCD

Welcome

Safety and Feasibility of the Supira System in High-Risk Percutaneous Coronary Interventions: 90-Day Results from the US SUPPORT I Early Feasibility Study (EFS)

Case 3: My Patient is on 6 Anti-Hypertensives - Are They Taking Them? and Is Renal Denervation Futile?

Durable Safety and Efficacy of Renal Denervation using the Symplicity Spyral Catheter in Patients Taking Antihypertensive Drugs: Final, 3-Year Results from the SPYRAL HTN-ON MED Randomized Study

Clinical Experience With a Novel Perfusion Balloon Catheter in Patients With Coronary Artery Perforation: Primary Results From the Ringer Clinical Study

What Are the Major Challenges?

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Initial Results from the First-in-Human Study of the Supira System

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

Securing Reimbursement: The Pathway to Financial Stability

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

It’s Time We Had These Devices Approved and Reimbursed

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content